ProfileGDS4814 / ILMN_1908307
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 8% 19% 22% 11% 22% 18% 4% 4% 3% 1% 10% 36% 10% 22% 2% 18% 10% 37% 66% 20% 1% 6% 35% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)40.53578
GSM780708Untreated after 4 days (C2_1)43.381119
GSM780709Untreated after 4 days (C3_1)43.948122
GSM780719Untreated after 4 days (C1_2)41.498611
GSM780720Untreated after 4 days (C2_2)43.940522
GSM780721Untreated after 4 days (C3_2)43.023818
GSM780710Trastuzumab treated after 4 days (T1_1)38.81644
GSM780711Trastuzumab treated after 4 days (T2_1)38.72564
GSM780712Trastuzumab treated after 4 days (T3_1)38.14013
GSM780722Trastuzumab treated after 4 days (T1_2)34.79441
GSM780723Trastuzumab treated after 4 days (T2_2)41.194310
GSM780724Trastuzumab treated after 4 days (T3_2)46.859936
GSM780713Pertuzumab treated after 4 days (P1_1)41.065210
GSM780714Pertuzumab treated after 4 days (P2_1)43.948522
GSM780715Pertuzumab treated after 4 days (P3_1)37.27342
GSM780725Pertuzumab treated after 4 days (P1_2)43.021418
GSM780726Pertuzumab treated after 4 days (P2_2)41.228810
GSM780727Pertuzumab treated after 4 days (P3_2)46.979937
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)61.744666
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)43.490820
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)32.71361
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)39.98816
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)46.541835